Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia |
| |
Authors: | Fariba Yarandi Zahra Eftekhar Soheyla Kanani Parviz Hanjani |
| |
Institution: | a Department of Gynecological Oncology, Medicine School, Medical Sciences/University of Tehran, Tehran, Iran b Rosenfeld Cancer Center, Abington Memorial Hospital, Abington, Pennsylvania, USA |
| |
Abstract: | ObjectiveTo compare the efficacy of methotrexate and actinomycin D as single agents in first-line chemotherapy for women with low-risk gestational trophoblastic neoplasia (LR-GTN).MethodsA total of 131 women with LR-GTN were randomized to receive a weekly pulsed dose of 30 mg/m2 of methotrexate intramuscularly (n = 81) or a pulsed intravenous bolus of 1.25 mg/m2 of actinomycin D every 2 weeks (n = 50). An additional cycle was administered as consolidation treatment following normalization of the serum level of β-human chorionic gonadotropin (< 5 IU/L).ResultsComplete remission was achieved in 48.14% of patients in the methotrexate group and 90.00% in the actinomycin D group (P < 0.001). The mean number of treatment cycles needed to achieve response was lower in the actinomycin D group (4.8 vs 6.8). The risk of treatment failure was 26.4 greater with methotrexate than with actinomycin D (95% confidence interval, 5.7-22.6; P < 0.001).ConclusionActinomycin D may be a better option than methotrexate as a first-line chemotherapy agent for patients with LR-GTN. |
| |
Keywords: | Actinomycin D Gestational trophoblastic neoplasia Methotrexate Single-agent chemotherapy |
本文献已被 ScienceDirect 等数据库收录! |